The company has announced its expectation to record a consolidated net loss of no less than HK$15.1 million for the first half of 2026, compared to a consolidated net loss of approximately HK$36.8 million for the same period in 2025.

According to the announcement, the anticipated loss for the period is primarily attributable to (i) a fair value loss on financial assets at fair value through profit or loss of approximately HK$24.9 million, which mainly includes unrealized losses from fair value changes in listed equity securities; and (ii) an impairment loss on loans and interest receivable of approximately HK$1.7 million.

The investment performance of the group has been impacted by the specific performance of certain sectors, particularly the healthcare industry.